Pfizer and BioNTech initiated rolling submission of Biologics License Application for FDA approval of COVID-19 vaccine
On May 7, 2021, Pfizer and BioNTech announced the initiation of a Biologics License Application (BLA) with the…
-
-
Moderna announced agreement with Switzerland for 7 million booster vaccine doses in 2022 with options
On May 6, 2021, Moderna announced a new supply agreement with the Swiss Federal Government for 7 million…
-
Novavax and Gavi executed advance purchase agreement for COVID-19 vaccine for COVAX facility
On May 6, 2021, Novavax announced that it had finalized an advance purchase agreement (APA) with Gavi, the…
-
Pfizer and BioNTech announced supplying COVID-19 vaccine for Olympic athletes at 2020 Tokyo games
On May 6, 2021, Pfizer announced the signing of a Memorandum of Understanding (MoU) with the International Olympic…
-
NEJM published phase 2b clinical trial results demonstrating efficacy of COVID-19 vaccine against B.1.351 variant
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
-
Pfizer and BioNTech received Health Canada authorization of COVID-19 vaccine in adolescents
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
-
Moderna announced expansion of its manufacturing technology center in Massachusetts
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
-
WHO welcomed Sweden’s announcement to share COVID-19 vaccine doses with COVAX
On May 3, 2021, the World Health Organization (WHO) welcomed the Government of Sweden’s announcement to share 1…
-
Data from Vaxart oral COVID-19 vaccine phase I study suggested broad cross-reactivity against Coronaviruses
On May 3, 2021, Vaxart announced that new data obtained from its Phase I COVID-19 trial added to…
-
Moderna announced supply agreement with Gavi for up to 500 million doses of COVID-19 Vaccine Moderna for COVAX
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million…
-
Novavax initiated pediatric expansion for phase 3 clinical trial of COVID-19 vaccine
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
-
Gavi signed agreement with Moderna to secure doses on behalf of COVAX Facility
On May 3, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Moderna…
-
Moderna announced Emergency Use listing granted by the WHO for its COVID-19 vaccine
On Apr. 30, 2021, Moderna announced the World Health Organization (WHO) had listed the Moderna COVID-19 vaccine (mRNA…
-
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
-
Pfizer and BioNTech submitted request to expand conditional marketing authorization of COMIRNATY in EU to adolescents
On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization…
-
Lonza and Moderna entered agreement to double drug substance production for COVID-19 vaccine in Visp
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…
-
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in ad itional…
-
CDC | COVID-19 | Infectious Disease | Vaccine
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
-
VBI Vaccines announced publication of Challenge Study Data of its eVLP vaccine candidate against COVID-19
On Apr. 28, 2021, VBI Vaccines announced that preclinical data of VBIﾒs enveloped virus-like particle (eVLP) vaccine candidate,…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
-
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s…
-
COVID-19 infections survey revealed significant reductions in COVID-19 infections with single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
-
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
-
The WHO announced continued review of emerging evidence on AstraZeneca COVID-19 vaccines
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
-
Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ﾙ adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
-
RTS,S malaria vaccine reached more than 650 000 children in Ghana, Kenya and Malawi through pilot programme
On Apr. 20, 2021, the World Health Organization (WHO) announced that two years on from the launch of…
-
Johnson & Johnson COVID-19 vaccine roll-out resumed in Europe following EMA review
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
-
Pfizer and BioNTech supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
-
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
-
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
